New Hampshire House Lets Marijuana Legalization And Psilocybin Therapy Bills Die Without A Vote
#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
The failure to advance psilocybin therapy legislation in New Hampshire delays potential clinical pathways for treating treatment-resistant depression and PTSD, conditions for which psychedelic-assisted therapy shows promising evidence in controlled settings. Clinicians in New Hampshire will continue operating without state-level frameworks or research infrastructure to support psychedelic medicine, limiting their ability to participate in emerging therapeutic protocols or refer patients to regulated clinical trials. This legislative inaction widens the gap between clinical evidence and practice access, potentially pushing patients toward unregulated sources rather than evidence-based medical supervision.
New Hampshire’s House of Representatives allowed bills proposing marijuana legalization and psilocybin-assisted therapy to expire without floor votes, preventing advancement of either measure during the legislative session. The failed psilocybin bill would have established a therapeutic program and funding mechanism for research into expanding psychedelic-assisted treatments beyond psilocybin. This legislative inaction maintains New Hampshire’s current prohibition on both recreational cannabis and psilocybin therapy, leaving the state out of the growing number of jurisdictions moving toward legalization or therapeutic access. For clinicians in New Hampshire, this means patients cannot legally access cannabis or psilocybin-assisted therapies within the state, potentially limiting treatment options for conditions like chronic pain, anxiety, and PTSD where emerging evidence suggests these therapies may be beneficial. Patients seeking these treatments may be forced to travel to neighboring states or forego evidence-informed options available elsewhere. Clinicians should remain informed about neighboring state programs and consider advocating for future legislative efforts if they believe these therapies would benefit their patient populations.
“When legislatures fail to advance evidence-based cannabis and psychedelic research, they’re essentially telling patients with treatment-resistant conditions that political risk matters more than their access to potentially life-changing medicine, and that’s a clinical failure we should be honest about.”
? While New Hampshire’s decision to let psychedelic therapy and cannabis legalization bills expire without legislative action may disappoint advocates, clinicians should recognize that the absence of state-level legalization does not preclude engagement with emerging evidence on these compounds. The failure to advance these bills reflects genuine policy complexities around regulatory frameworks, clinical safety infrastructure, and public readiness that merit cautious deliberation rather than swift implementation. However, healthcare providers should remain informed about evolving research on psilocybin-assisted therapy for treatment-resistant conditions and cannabis for specific indications, as federal policy and neighboring states’ experiences will likely continue shaping the clinical landscape. The lack of dedicated state funding for psychedelic research studies also means clinicians must critically appraise evidence from other jurisdictions and maintain awareness of any federally-sponsored trials their patients might access. Practically, providers should use clinical encounters to assess patient interest in these emerging therapies, understand their own knowledge
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
Read next
